Table 280 Total iron and colorectal cancer risk. Main characteristics of studies identified in the CUP SLR Cases/ Author, Year, Study name, Study size Case Exposure RR (95%CI) Adjustment WCRF Code, Outcome Comparison characteristics Follow-up ascertainment assessment Ptrend factors Country Gay, 2012 EPIC-Norfolk, 185/ Cancer registry 7-day dietary Incidence, COL40920 Case-only 25 636 recalls colorectal per 1 sd units 1.05 (0.59-1.88) UK Age: 45-79 11 years cancer, gc:at years, mutations Age, sex, M/W smoking Apc promoter methylation per 1 sd units 0.77 (0.51-1.16) ≥20% Apc mutations per 1 sd 1.18 (0.84-1.69) Zhang, 2011 NHS-HPFS, 1 079/ Medical records FFQ Incidence, Age, alcohol vs 0-10.9 1.11 (0.88-1.41) ≥22.7 COL40891 Prospective 115 061 and pathology colorectal consumption, mg/day Ptrend:0.44 USA Cohort, 22 years reports cancer, women aspirin use, M/W, BMI, calcium 1 035/ Men vs 0-12.6 1.08 (0.84-1.38) ≥24.6 nurses & health Intake, mg/day Ptrend:0.61 professionals endoscopy, 837/ Incidence, colon vs 0-10.9 1.03 (0.79-1.36) ≥22.7 energy-adjusted cancer, women mg/day Ptrend:0.87 folate, history of colorectal 815/ Men vs 0-12.6 1.14 (0.85-1.51) ≥24.6 cancer, HRT mg/day Ptrend:0.59 use, physical 242/ Incidence, rectal vs 0-10.9 1.44 (0.90-2.33) activity, ≥22.7 cancer, women mg/day Ptrend:0.05 smoking, vitamin d, zinc 208/ Men vs 0-12.6 0.94 (0.55-1.60) ≥24.6 intake mg/day Ptrend:0.91
Table 280 Total iron and colorectal cancer risk. Main characteristics of studies identified in the CUP SLR Author, Year, WCRF Code, Country Study name, characteristics Cases/ Study size Follow-up Case ascertainment Exposure assessment Outcome Comparison RR (95%CI) Ptrend Adjustment factors Gay, 2012 COL40920 UK EPIC-Norfolk, Case-only Age: 45-79 years, M/W 185/ 25 636 11 years Cancer registry 7-day dietary recalls Incidence, colorectal cancer, gc:at mutations per 1 sd units 1.05 (0.59-1.88) Age, sex, smoking Apc promoter methylation ≥20% per 1 sd units 0.77 (0.51-1.16) Apc mutations per 1 sd 1.18 (0.84-1.69) Zhang, 2011 COL40891 USA NHS-HPFS, Prospective Cohort, M/W, nurses & health professionals 1 079/ 115 061 22 years Medical records and pathology reports FFQ Incidence, colorectal cancer, women ≥22.7 vs 0-10.9 mg/day 1.11 (0.88-1.41) Ptrend:0.44 Age, alcohol consumption, aspirin use, BMI, calcium Intake, endoscopy, energy-adjusted folate, history of colorectal cancer, HRT use, physical activity, smoking, vitamin d, zinc intake 1 035/ Men ≥24.6 vs 0-12.6 mg/day 1.08 (0.84-1.38) Ptrend:0.61 837/ Incidence, colon cancer, women ≥22.7 vs 0-10.9 mg/day 1.03 (0.79-1.36) Ptrend:0.87 815/ Men ≥24.6 vs 0-12.6 mg/day 1.14 (0.85-1.51) Ptrend:0.59 242/ Incidence, rectal cancer, women ≥22.7 vs 0-10.9 mg/day 1.44 (0.90-2.33) Ptrend:0.05 208/ Men ≥24.6 vs 0-12.6 mg/day 0.94 (0.55-1.60) Ptrend:0.91
CUP_colorectal_SLR_2016_RO.docx